[POLITICO Pro] 80-group campaign targeting hepatitis drug cost

05-28-2014 MediaPress Release

“More than 80 organizations are launching the Campaign for Sustainable Rx Pricing to bring the pharmaceutical company Gilead to the table to negotiate a lower price, hoping that public pressure will prevail where private entreaties have not. John Rother, CEO of the National Coalition on Health Care, said Gilead’s pricing amounts to ‘an abuse of […]

[Vox.com] The fiercest debate in health care is about a $1,000 pill

05-28-2014 Press Release

“The people who pay for drugs aren’t fully buying those arguments — and want Sovaldi to back off its prices. They argue that Gilead could more than cover the costs of drug development and even run a profit with a lower price. This year alone, analysts expect Sovaldi to generate as much as $15 billion […]

[Kaiser Health News] ‘National Dialogue’ Urged On Cost Of New Hepatitis C Drug

05-28-2014 Press Release

“The outcry continues over the $1,000-a-pill hepatitis C drug made by California-based Gilead Sciences. While the drug is a significant advance over older treatments for the viral liver disease, the price set by the company ‘represents an abuse of market power,’ said John Rother, president and CEO of the National Coalition on Health Care, which […]


05-28-2014 Press Release

“A broad coalition of health care groups is trying to compel the pharmaceutical company Gilead to slim down its profits on the multibillion-dollar hepatitis drug. The “miracle” med costs about $84,000 for a 12-week treatment that effectively cures hepatitis C more than 90 percent of the time — far more effective than earlier drugs that […]

[CNBC] The $84,000 question: Will focusing on drug prices rein in costs?

05-22-2014 Press Release

By Meg Tirrell May 22, 2014   The mounting scrutiny of prescription drug prices in the U.S. reached fever pitch when a new drug for hepatitis C was priced at about $1,000 a day. Gilead Sciences’ Sovaldi, approved in December, cures the viral liver infection in most cases. it takes about 12 weeks, and costs […]

[MedPage Today] Medicaid Directors Question Need for $1,000 HCV Pill

05-22-2014 Press Release

By Michael Smith May 22, 2014   The evidence base for one of the star hepatitis C drugs is poor and the guidelines for its use are flawed, according to a report prepared for the National Association of Medicaid Directors. According to the report, studies of sofosbuvir (Sovaldi) are generally of poor quality, mostly directed […]

[The Hill] Insurance lobby: Let’s beat government to drug cost reform

05-21-2014 Press Release

By Ferdous Al-Faruque May 21, 2014   The top health insurance lobbyist in the country says stakeholders are at a “crossroad” on addressing the growing cost of specialty medications themselves before the government steps in. During a panel discussion Wednesday, Karen Ignagni, president of America’s Health Insurance Plans, said insurance companies, drugmakers and pharmacy benefit managers […]

[Modern Healthcare] Excessive drug costs could invite price caps: AHIP’s Ignagni

05-21-2014 Press Release

By Paul Demko May 21, 2014   The steep cost of Sovaldi—Gilead Sciences’ $1,000-per-pill treatment for hepatitis C—is prompting wide-ranging discussions about the cost of drugs and whether the government should take more steps to regulate the cost of potentially life-saving treatments. “The Sovaldi example has brought us to a crossroads,” said Karen Ignagni, president […]

[Law360] Drugmakers, Insurers Battle Over Surging Big Pharma Prices

05-21-2014 Press Release

By Jeff Overly May 21, 2014   Executives representing drugmakers, employers and health insurers sparred Wednesday at a high-profile forum on soaring prescription drug prices, clashing over the need for higher-deductible plans, government cost controls and streamlined approvals at the U.S. Food and Drug Administration. The event, dubbed Future of Medicine and held in Washington, […]

[Healthcare Payer News] Sovaldi spurs call to action on high drug costs

05-21-2014 Press Release

By Anthony Brino May 21, 2014   The breakthrough hepatitis drug Sovaldi has sparked a vigorous debate about the financial sustainability of U.S. healthcare and the role of government in regulating prices. “The Sovaldi example has brought us to a crossroads,” said Karen Ignagni, president and CEO of America’s Health Insurance Plans, during a conference […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.